Close Menu

NEW YORK – Thermo Fisher Scientific said on Monday that it estimates reported and organic year-over-year revenue growth for Q1 to be in the range of 1 to 2 percent.

In the face of the developing COVID-19 pandemic, the company also withdrew its guidance for 2020.

Thermo Fisher said it is supporting the global COVID-19 response with products and services that help analyze, diagnose, and protect from the virus. But as the pandemic spread throughout the world, the company saw a "significant reduction in customer activity" by late March.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Washington Post reports that US states and territories are seeking more funding for the distribution of SARS-CoV-2 vaccines.

The strain now accounts for about 80 percent of cases in Wales and Scotland, and about half of cases in England, the Guardian reports.

A new study suggests that using CRISPR to edit human embryonic DNA can lead to the loss of whole chromosomes, as the Associated Press reports.

In Science this week: ancient dog genomes highlight long ties with humans, genomic analysis of 40,000-year-old early East Asian individual, and more.